LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on activators of free fatty acid receptors (GPR120) implicated in the development of non-alcoholic steatohepatitis (NASH), the investment is part of a £2million fund raise to support the optimisation of a lead candidate to progress to later pre-clinical development. LifeArc is joined in this investment by founding investor Epidarex Capital.
Professor Graeme Milligan, co-founder of Caldan Therapeutics and colleague Dr Brian Hudson have jointly authored a review entitled “FFA4/GPR120: Pharmacology and Therapeutic Opportunities” (Trends Pharmacol. Sci. 2017 Sep;38(9):809-821) PMID: 28734639. Substantial focus on the therapeutic potential of FFA4/GPR120 is currently directed towards metabolic diseases however high levels of expression of FFA4/GPR120 in the lung suggest utility in analysis of the potential therapeutic roles of FFA4/GPR120 ligands in both acute and chronic airway inflammatory conditions.
The University of Edinburgh today announced that Dr Frank Armstrong, Chairman of Caldan Therapeutics, was appointed as a member of the University Court, the governing body of the University of Edinburgh, and of its Policies and Resources committee.
Caldan Therapeutics is pleased to announce the appointment of Dr Mark Payton as Chief Executive Officer (CEO) who brings extensive experience of growing organisations across all aspects of the biotech environment
Professor Graeme Milligan, co-founder of Caldan Therapeutics, has been named as a 2016 Highly Cited Researcher a distinction that very few researchers attain. His reports rank among the top 1% most cited works for being the most valuable and significant in their subject field in their year of publication, earning them the mark of exceptional impact.
Caldan Therapeutics, a 2015 ‘Spin Out’ from the University of Glasgow and the University of Southern Denmark was named as ‘Early Stage/Risk Capital Deal of the Year’ at the 2016 ‘Insider Deals and Dealmakers’ awards event held at the Hilton Hotel in Glasgow on the 7th September. Caldan Therapeutics, which focuses on the early stage discovery of novel treatments for type II diabetes and related conditions, raised £4.45 million in Series A funding through investments led by Epidarex Capital and the Scottish Investment Bank.
Professor Graeme Milligan, co-founder of Caldan Therapeutics, has been awarded the prestigious JR Vane Medal by the British Pharmacological Society for his outstanding work in the field of molecular, cellular and signalling pharmacology.
Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes, is pleased to announce the following appointments:
Caldan Therapeutics Ltd (Caldan) has announced a £4.45 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Eli Lilly and Company is one of numerous limited partners in the fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round.
Caldan Therapeutics Ltd
7-11 Melville Street,
Company Registration No SC515558
Contact via email only